US Pharma MarketingThe post Pilatus doses first patient in Phase I PLT012 trial for HCC appeared first on Clinical Trials Arena.
Pilatus doses first patient in Phase I PLT012 trial for HCC
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing PLT012, an investigational therapy for HCC. The Chinese University of Hong Kong is conducting the study at the Phase I Clinical Trial Centre. The trial intends to use the clinical findings to guide the future development of PLT012 across liver disease. Credit: Shidlovski/Shutterstock.com. Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing PLT012, an investigational therapy for hepatocellular carcinoma (HCC). The administration occurred within the biomarker backfill cohort, which…
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing PLT012, an investigational therapy for HCC.
Source: Clinical Trials Arena